Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of $43.66 per American Depositary Receipt (ADR) for a specific notional investment adjustment.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific administrative adjustment within the US Retirement Savings Plan ("The Plan").
Management Commentary and Risks
The filing notes a re-valuation of the cash element of a notional investment held in GSK Ordinary share ADRs. Consequently, the Plan Administrators notified the company and the relevant individual of an increase in the notional allocation of Ordinary share ADRs on April 29, 2011. This transaction was executed in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c). No broader outlook, risks, or contingencies are discussed.
Important Facts for Investors
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Individual Involved: Dr. K. Slaoui (Connected Person of Director Dr. M. M. Slaoui).
- Quantity: 4 shares.
- Price: $43.66 per ADR.
- Date of Transaction: April 29, 2011.
- Notification Date: May 3, 2011.